Buy Rating on CNTB: Fast-Acting Rademikibart Data Underscore Differentiation and Long-Term Respiratory Opportunity

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings and keeping the price target at $7.00.

Brandon Folkes has given his Buy rating due to a combination of factors tied to the recent Phase 1 IV rademikibart data and its implications for CNTB’s pipeline. He views the rapid and meaningful improvements in lung function, seen within minutes and lasting nearly a month, as strong confirmation of the drug’s fast-acting profile and differentiation versus current IL‑4Rα biologics, particularly in the underserved setting of acute asthma and COPD exacerbations.

Folkes also emphasizes that the notably robust and consistent FEV1 gains in COPD patients strengthen confidence in both the mechanism and commercial opportunity, despite some early variability in the smaller asthma cohort. In his view, the market’s negative reaction does not align with the data’s support for the core thesis ahead of the key Seabreeze Phase 2 readout in mid‑2026, leaving the current share price dislocated from the long‑term potential in both acute and chronic respiratory indications.

In another report released yesterday, Lake Street also maintained a Buy rating on the stock with a $9.00 price target.